Martin JC, Hoegel TJ, Lynch ML, Woloszynska A, Melendy T, Ohm JE. Exploiting replication stress as a novel therapeutic intervention. Mol Cancer Res. 2021;19:192–206.
Google Scholar
Gaillard H, García-Muse T, Aguilera A. Replication stress and cancer. Nat Rev Cancer. 2015;15:276–89.
Google Scholar
Su XA, Ma D, Parsons JV, Replogle JM, Amatruda JF, Whittaker CA, et al. RAD21 is a driver of chromosome 8 gain in Ewing sarcoma to mitigate replication stress. Genes Dev. 2021;35:556–72.
Google Scholar
Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, et al. 18F-FLT positron emission tomography (PET) is a pharmacodynamic marker for EWS-FLI1 activity and Ewing sarcoma. Sci Rep. 2016;6:33926.
Google Scholar
Tang S-W, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, et al. SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing sarcoma. Clin Cancer Res. 2015;21:4184–93.
Google Scholar
Murai J, Thomas A, Miettinen M, Pommier Y. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. Pharmacol Ther. 2019;201:94–102.
Google Scholar
Mondal G, Stevers M, Goode B, Ashworth A, Solomon DA. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers. Nat Commun. 2019;10:1686.
Google Scholar
Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014;10:e1004475.
Google Scholar
Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014;4:1326–41.
Google Scholar
Gorthi A, Bishop AJR. Ewing sarcoma fusion oncogene: at the crossroads of transcription and DNA damage response. Mol Cell Oncol. 2018;5:e1465014.
Google Scholar
Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, et al. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature. 2018;555:387–91.
Google Scholar
Gracilla DE, Menon S, Breese MR, Lin YP, Dela Cruz FS, Feinberg TY, et al. FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. Cancer Res. 2026;86:2660–77.
Google Scholar
Koppenhafer SL, Goss KL, Terry WW, Gordon DJ. Inhibition of the ATR-CHK1 pathway in Ewing sarcoma cells causes DNA damage and apoptosis via the CDK2-mediated degradation of RRM2. Mol Cancer Res. 2020;18:91–104.
Google Scholar
Goss KL, Koppenhafer SL, Harmoney KM, Terry WW, Gordon DJ. Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine. Oncotarget. 2017;8:87016–32.
Google Scholar
Goss KL, Gordon DJ. Gene expression signature-based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. Oncotarget. 2016;7:63003–19.
Google Scholar
Croushore EE, Koppenhafer SL, Goss KL, Geary EL, Gordon DJ. Activator protein-1 (AP-1) signaling inhibits the growth of Ewing sarcoma cells in response to DNA replication stress. Cancer Res Commun. 2023;3:1580–93.
Google Scholar
Sturm M-J, Henao-Restrepo JA, Becker S, Proquitté H, Beck JF, Sonnemann J. Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing’s sarcoma cells. J Cancer Res Clin Oncol. 2023;149:8605–17.
Google Scholar
Nieto-Soler M, Morgado-Palacin I, Lafarga V, Lecona E, Murga M, Callen E, et al. Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget. 2016;7:58759–67.
Google Scholar
Jess J, Sorensen KM, Boguslawski EA, Stout MC, Madaj ZB, Caiello BP, et al. Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma. Clin Cancer Res. 2024;30:3533–48.
Google Scholar
Koppenhafer SL, Geary EL, Thomas MV, Croushore EE, Zimmerman JAO, Gedminas JM, et al. Histone deacetylase inhibitors target DNA replication regulators and replication stress in Ewing sarcoma cells. Cancer Res Commun. 2025;5:1034–48.
Google Scholar
Long MJC, Ly P, Aye Y. Still no rest for the reductases: ribonucleotide reductase (RNR) structure and function: an update. Subcell Biochem. 2022;99:155–97.
Google Scholar
Rundle S, Bradbury A, Drew Y, Curtin NJ. Targeting the ATR-CHK1 axis in cancer therapy. Cancers. 2017.
Orecki L, Andrs M, Korabecny J. Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer. Cancers (Basel). 2021;13:795..
Koppenhafer SL, Goss KL, Terry WW, Gordon DJ. mTORC1/2 and protein translation regulate levels of CHK1 and the sensitivity to CHK1 inhibitors in Ewing sarcoma cells. Mol Cancer Ther. 2018;17:2676–88.
Google Scholar
Ziener J, Henao-Restrepo JA, Leonhardi J, Sturm M-J, Becker S, Morales-Prieto DM, et al. Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing’s sarcoma cells. BMC Cancer. 2025;25:277.
Google Scholar
Martin JC, Sims JR, Gupta A, Bakin AV, Ohm JE. WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe. Cancer Res Commun. 2022;2:471–82.
Google Scholar
Ohmura S, Marchetto A, Orth MF, Li J, Jabar S, Ranft A, et al. Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol Cancer. 2021;20:97.
Google Scholar
Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2012;2:524–39.
Google Scholar
Branigan TB, Kozono D, Schade AE, Deraska P, Rivas HG, Sambel L, et al. MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity. Cell Rep. 2021;34:108808.
Google Scholar
Zuazua-Villar P, Rodriguez R, Gagou ME, Eyers PA, Meuth M. DNA replication stress in CHK1-depleted tumour cells triggers premature (S-phase) mitosis through inappropriate activation of Aurora kinase B. Cell Death Dis. 2014;5:e1253.
Google Scholar
Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res. 2005;65:6835–42.
Google Scholar
Mak JPY, Man WY, Chow JPH, Ma HT, Poon RYC. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells. Oncotarget. 2015;6:21074–84.
Google Scholar
Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle. 2006;5:1983–8.
Google Scholar
Niida H, Tsuge S, Katsuno Y, Konishi A, Takeda N, Nakanishi M. Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J Biol Chem. 2005;280:39246–52.
Google Scholar
Goss KL, Koppenhafer SL, Waters T, Terry WW, Wen K-K, Wu M, et al. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. Oncogene. 2021;40:564–77.
Google Scholar
Koppenhafer SL, Goss KL, Voigt E, Croushore E, Terry WW, Ostergaard J, et al. Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in Ewing sarcoma. Oncogene. 2022;41:2873–84.
Google Scholar
Grant GD, Kedziora KM, Limas JC, Cook JG, Purvis JE. Accurate delineation of cell cycle phase transitions in living cells with PIP-FUCCI. Cell Cycle. 2018;17:2496–516.
Google Scholar
Kanda T, Sullivan KF, Wahl GM. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol. 1998;8:377–85.
Google Scholar
Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009;6:275–7.
Google Scholar
Goodman CA, Mabrey DM, Frey JW, Miu MH, Schmidt EK, Pierre P, et al. Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. FASEB J. 2011;25:1028–39.
Google Scholar
Nagelreiter F, Coats MT, Klanert G, Gludovacz E, Borth N, Grillari J, et al. OPP labeling enables total protein synthesis quantification in CHO production cell lines at the single-cell level. Biotechnol J. 2018;13:e1700492.
Google Scholar
Forester CM, Zhao Q, Phillips NJ, Urisman A, Chalkley RJ, Oses-Prieto JA, et al. Revealing nascent proteomics in signaling pathways and cell differentiation. Proc Natl Acad Sci USA 2018;115:2353–8.
Google Scholar
da Costa AABA, Chowdhury D, Shapiro GI, D’Andrea AD, Konstantinopoulos PA. Targeting replication stress in cancer therapy. Nat Rev Drug Discov. 2023;22:38–58.
Google Scholar
Sørensen CS, Syljuåsen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 2012;40:477–86.
Google Scholar
Huang X, Darzynkiewicz Z. Cytometric assessment of histone H2AX phosphorylation: a reporter of DNA damage. Methods Mol Biol. 2006;314:73–80.
Google Scholar
Ubhi T, Brown GW. Exploiting DNA replication stress for cancer treatment. Cancer Res. 2019;79:1730–9.
Google Scholar
Salic A, Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA 2008;105:2415–20.
Google Scholar
Kari S, Subramanian K, Altomonte IA, Murugesan A, Yli-Harja O, Kandhavelu M. Programmed cell death detection methods: a systematic review and a categorical comparison. Apoptosis. 2022;27:482–508.
Google Scholar
Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953–66.
Google Scholar
Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig P-A, et al. The target landscape of clinical kinase drugs. Science. 2017;358:eaan4368.
Google Scholar
King C, Diaz HB, McNeely S, Barnard D, Dempsey J, Blosser W, et al. LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms. Mol Cancer Ther. 2015;14:2004–13.
Google Scholar
Zhou L, Cai X, Han X, Xu N, Chang DC. CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl-2/Bax family proteins during treatment with microtubule-interfering agents. Cell Biol Int. 2014;38:737–46.
Google Scholar
Castedo M, Perfettini JL, Roumier T, Kroemer G. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ. 2002;9:1287–93.
Google Scholar
Kim G, Jang S-K, Ahn SH, Kim S, Park CS, Seong M-K, et al. Proapoptotic role of CDK1 in overcoming paclitaxel resistance in ovarian cancer cells in response to combined treatment with paclitaxel and duloxetine. Cancer Cell Int. 2024;24:409.
Google Scholar
Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA 2006;103:10660–5.
Google Scholar
Lazo JS, Aslan DC, Southwick EC, Cooley KA, Ducruet AP, Joo B, et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem. 2001;44:4042–9.
Google Scholar
Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009;8:2992–3000.
Google Scholar
Gallo D, Young JTF, Fourtounis J, Martino G, Álvarez-Quilón A, Bernier C, et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022;604:749–56.
Google Scholar
Alber AB, Suter DM. Dynamics of protein synthesis and degradation through the cell cycle. Cell Cycle. 2019;18:784–94.
Google Scholar
Tarn W-Y, Lai M-C. Translational control of cyclins. Cell Div. 2011;6:5.
Google Scholar
Pellarin I, Dall’Acqua A, Favero A, Segatto I, Rossi V, Crestan N, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther. 2025;10:11.
Google Scholar
Martin JC, Sims JR, Gupta A, Hagoel TJ, Gao L, Lynch ML, et al. CDC7 kinase (DDK) inhibition disrupts DNA replication leading to mitotic catastrophe in Ewing sarcoma. Cell Death Discov. 2022;8:85.
Google Scholar
Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G, et al. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell. 2015;28:557–68.
Google Scholar
Matthess Y, Raab M, Sanhaji M, Lavrik IN, Strebhardt K. Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol Cell Biol. 2010;30:5726–40.
Google Scholar
Hou Y, Allan LA, Clarke PR. Phosphorylation of XIAP by CDK1-cyclin-B1 controls mitotic cell death. J Cell Sci. 2017;130:502–11.
Google Scholar
Harley ME, Allan LA, Sanderson HS, Clarke PR. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 2010;29:2407–20.
Google Scholar
Han CR, Jun DY, Lee JY, Kim YH. Prometaphase arrest-dependent phosphorylation of Bcl-2 and Bim reduces the association of Bcl-2 with Bak or Bim, provoking Bak activation and mitochondrial apoptosis in nocodazole-treated Jurkat T cells. Apoptosis. 2014;19:224–40.
Google Scholar
Andersen JL, Johnson CE, Freel CD, Parrish AB, Day JL, Buchakjian MR, et al. Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2. EMBO J. 2009;28:3216–27.
Google Scholar
Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Matta H, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002;62:5897–901.
Google Scholar
Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Ewing’s sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res. 2001;61:2704–12.
Google Scholar
de Hooge ASK, Berghuis D, Santos SJ, Mooiman E, Romeo S, Kummer JA, et al. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin Cancer Res. 2007;13:206–14.
Google Scholar
Kang Z, Goldstein SD, Yu Y, Meltzer PS, Loeb DM, Cao L. Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing’s sarcoma. Br J Cancer. 2015;113:894–901.
Google Scholar
Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001;20:5865–77.
Google Scholar
Lockhead S, Moskaleva A, Kamenz J, Chen Y, Kang M, Reddy AR, et al. The apparent requirement for protein synthesis during G2 phase is due to checkpoint activation. Cell Rep. 2020;32:107901.
Google Scholar
Hinds JW, Ditano JP, Eastman A. Inhibition of protein synthesis induced by CHK1 inhibitors discriminates sensitive from resistant cancer cells. ACS Pharm Transl Sci. 2021;4:1449–61.
Google Scholar
Ditano JP, Eastman A. Comparative activity and off-target effects in cells of the CHK1 inhibitors MK-8776, SRA737, and LY2606368. ACS Pharm Transl Sci. 2021;4:730–43.
Google Scholar
Ogawa A, Izumikawa K, Tate S, Isoyama S, Mori M, Fujiwara K, et al. SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis. Mol Cell. 2025;85:894–912.e10.
Google Scholar
Boon NJ, Oliveira RA, Körner P-R, Kochavi A, Mertens S, Malka Y, et al. DNA damage induces p53-independent apoptosis through ribosome stalling. Science. 2024;384:785–92.
Google Scholar
Gartrell J, Mellado-Largarde M, Clay MR, Bahrami A, Sahr NA, Sykes A, et al. SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to replicative stress caused By DNA-damaging agents. Mol Cancer Ther. 2021;20:2151–65.
Google Scholar
